Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Over the last years a rising medical need for treatment of chronic pain was identified. Based
on previous findings indicating the pain modulating effects of cannabinoids in chronic pain
disorders, this clinical trial investigates the efficacy and tolerability of the THC-focused
nano endocannabinoid system modulator AP707 in patients with chronic pain disorders due to
central neuropathy of any genesis. Patients receive AP707 or placebo over the course of 14
weeks as an add-on to the standard of care. Changes in pain intensity, quality of life and
sleep and others measures are monitored through different scales to assess the efficacy of
AP707 in patients with chronic pain due to central neuropathy of any genesis.